1 Brooling J, Leal R. Secondary Sclerosing Cholangitis: a Review of Recent Literature. Curr Gastroenterol Rep 2017; 19: 44 [PMID: 28752474 DOI: 10.1007/s11894-017-0583-8]
2 Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 190-209 [PMID: 27085692 DOI: 10.1016/j.ejca.2016.02.025]
3 Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017; 28: 2377-2385 [PMID: 28945858 DOI: 10.1093/annonc/mdx286]
4 de La Rochefoucauld J, Noël N, Lambotte O. Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Intern Emerg Med 2020; 15: 587-598 [PMID: 32144552 DOI: 10.1007/s11739-020-02295-2]
5 Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 2017; 35: 529-536 [PMID: 28317087 DOI:10.1007/s10637-017-0453-0]
6 Sandrasegaran K, Alazmi WM, Tann M, Fogel EL, McHenry L, Lehman GA. Chemotherapy-induced sclerosing cholangitis. Clin Radiol 2006; 61: 670-678 [PMID: 16843750 DOI: 10.1016/j.crad.2006.02.013]
7 Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. Biochim Biophys Acta Mol Basis Dis 2018; 1864: 1498-1506 [PMID: 28882625 DOI: 10.1016/j.bbadis.2017.08.033]
8 Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol 2015; 33: 2092- 2099 [PMID: 25918278 DOI: 10.1200/JCO.2014.60.0379]
9 Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, Urba WJ, Leidner RS. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 2019; 7: 165 [PMID: 31269983 DOI: 10.1186/s40425-019-0645-6]
10 Hanrahan P, Van Der Westhuizen A, Collins S, Owens D, Hersey P. Delayed autoimmune effects in patients treated with antibodies against the checkpoint inhibitor PD1. J Dtsch Dermatol Ges 2013; 11: 16 [DOI: 10.1111/ddg.12015_4]
11 Kanaoka K, Moriizumi K, Okada H, Iwahashi K, Tsuji H, Yasuoka H, Minami S. Pembrolizumab-Induced Delayed-Onset Hepatitis. Case Rep Gastroenterol 2020; 14: 586-592 [PMID: 33250701 DOI: 10.1159/000509953]
12 Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Hirata H, Yano Y, Yokota S, Kinehara Y, Naito Y, Otsuka T, Kanazu M, Kuroyama M, Hamaguchi M, Koba T, Futami Y, Ishijima M, Suga Y, Akazawa Y, Machiyama H, Iwahori K, Takamatsu H, Nagatomo I, Takeda Y, Kida H, Akbay EA, Hammerman PS, Wong KK, Dranoff G, Mori M, Kijima T, Kumanogoh A. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 2018; 3 [PMID: 30282824 DOI: 10.1172/jci.insight.59125]
13 Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26: 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353]
14 Zhu GQ, Shi KQ, Huang GQ, Wang LR, Lin YQ, Braddock M, Chen YP, Zhou MT, Zheng MH. A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. Oncotarget 2015; 6: 26757- 26769 [PMID: 26378046 DOI: 10.18632/oncotarget.5610]
15 Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95 [PMID: 29162153 DOI:10.1186/s40425-017-0300-z]
16 Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 2018; 67: 61-65 [PMID: 28913619 DOI: 10.1007/s00262-017-2062-3]
17 Koya Y, Shibata M, Shinohara N, Nebuya S, Oe S, Honma Y, Senju M, Sato N, Harada M. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work. Hepatol Res 2019; 49: 950-956 [PMID: 30861263 DOI: 10.1111/hepr.13329]
論文の公開元へ
